Clinical Trials
12 trialsNCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT05856695 2025-09-24
TAXIO
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT07022301 2025-06-15
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
First Affiliated Hospital of Wannan Medical College
Phase 2 Not yet recruiting
NCT06429696 2025-05-28
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT06851819 2025-02-28
TERE
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT05745350 2025-02-11
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT04462276 2025-01-30
TREASURE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06739928 2024-12-18
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Recruiting
NCT04967625 2021-07-28
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03253068 2020-05-19
Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Wakayama Medical University
Phase 2 Unknown
NCT03755115 2019-01-16
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT02179528 2014-09-12
Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
Peking University Cancer Hospital & Institute
Phase 2 Unknown